These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 8722345

  • 1. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
    Fleming RA, Cruz JM, Webb CD, Kucera GL, Perry JJ, Hurd DD.
    Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
    [Abstract] [Full Text] [Related]

  • 2. Combined intravenous and oral mesna in outpatients treated with ifosfamide.
    Goren MP, McKenna LM, Goodman TL.
    Cancer Chemother Pharmacol; 1997 Apr; 40(5):371-5. PubMed ID: 9272112
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM, Grinblatt DL, Malloy R, Williams SF.
    Cancer; 1998 Oct 15; 83(8):1540-5. PubMed ID: 9781947
    [Abstract] [Full Text] [Related]

  • 5. [Urinary bioavailability of sodium-2-mercaptoethanesulfonate (Uromitexan) following intravenous, subcutaneous and continuous subcutaneous administration].
    Roth B, Cerny T, Brunner KW, Küpfer A.
    Schweiz Med Wochenschr; 1989 Aug 26; 119(34):1153-8. PubMed ID: 2510294
    [Abstract] [Full Text] [Related]

  • 6. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    Semin Oncol; 1996 Jun 26; 23(3 Suppl 6):97-8. PubMed ID: 8677458
    [Abstract] [Full Text] [Related]

  • 7. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
    Pendyala L, Schwartz G, Smith P, Zdanowicz J, Murphy M, Hausheer F.
    Cancer Chemother Pharmacol; 2003 May 26; 51(5):376-84. PubMed ID: 12682786
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V, Wagner T.
    Cancer Chemother Pharmacol; 1997 May 26; 39(5):431-9. PubMed ID: 9054957
    [Abstract] [Full Text] [Related]

  • 10. Prevention of further cyclophosphamide induced hemorrhagic cystitis by hyperbaric oxygen and mesna in guinea pigs.
    Korkmaz A, Oter S, Deveci S, Goksoy C, Bilgic H.
    J Urol; 2001 Sep 26; 166(3):1119-23. PubMed ID: 11490309
    [Abstract] [Full Text] [Related]

  • 11. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
    Souid AK, Fahey RC, Dubowy RL, Newton GL, Bernstein ML.
    Cancer Chemother Pharmacol; 1999 Sep 26; 44(6):498-504. PubMed ID: 10550571
    [Abstract] [Full Text] [Related]

  • 12. Contribution of flavonoid antioxidants to the preventive effect of mesna in cyclophosphamide-induced cystitis in rats.
    Ozcan A, Korkmaz A, Oter S, Coskun O.
    Arch Toxicol; 2005 Aug 26; 79(8):461-5. PubMed ID: 15800758
    [Abstract] [Full Text] [Related]

  • 13. Cyclophosphamide-induced Down-Regulation of Uroplakin II in the Mouse Urinary Bladder Epithelium is Prevented by S-Allyl Cysteine.
    Abdi SA, Najmi AK, Raisuddin S.
    Basic Clin Pharmacol Toxicol; 2016 Dec 26; 119(6):598-603. PubMed ID: 27234646
    [Abstract] [Full Text] [Related]

  • 14. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
    Anderson LW, Chen TL, Colvin OM, Grochow LB, Collins JM, Kennedy MJ, Strong JM.
    Clin Cancer Res; 1996 Sep 26; 2(9):1481-7. PubMed ID: 9816324
    [Abstract] [Full Text] [Related]

  • 15. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Mace JR, Keohan ML, Bernardy H, Junge K, Niebch G, Romeis P, Thoma A, Wagner T, Mueller U, Demetri G, Baker LH.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5829-34. PubMed ID: 14676103
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
    Goren MP, Epelman S, Bush DA.
    Cancer Chemother Pharmacol; 2004 Sep 01; 54(3):237-40. PubMed ID: 15184993
    [Abstract] [Full Text] [Related]

  • 20. Low-dose cyclophosphamide associated with hemorrhagic cystitis in a breast cancer patient.
    Marshall A, McGrath C, Torigian D, Papanicolaou N, Lal P, Kaplan Tweed C.
    Breast J; 2012 Sep 01; 18(3):272-5. PubMed ID: 21972971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.